At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNY YieldMax MRNA Option Income Strategy ETF
Market Closed 09-18 16:00:00 EDT
33.69
-0.58
-1.69%
盘后33.66
-0.03-0.09%
19:52 EDT
High34.49Low33.16Vol194.00K
Open34.49D1 Closing34.27Amplitude3.88%
Mkt Cap146.72MTradable Cap146.72MTotal Shares4.35M
T/O6.57MT/O Rate4.45%Tradable Shares4.35M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide
TIPRANKS  ·  04:05
Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide
Cboe data shows mixed options sentiment in Moderna with shares down 1.49%
TIPRANKS  ·  09-18 23:05
Cboe data shows mixed options sentiment in Moderna with shares down 1.49%
LIVE Markets-Cash-Return Stocks Win Back Investor Favor, Leaving Megacaps Behind
Reuters  ·  09-18 22:51
LIVE Markets-Cash-Return Stocks Win Back Investor Favor, Leaving Megacaps Behind
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
TIPRANKS  ·  09-18 19:35
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
Moderna stock rises 8%: can it continue its cancer vaccine success rally?
Bellwether Stocks Movement  ·  09-18 14:04
Moderna stock rises 8%: can it continue its cancer vaccine success rally?
Moderna Inc. Stock Climbs 8.5%, Outperforms Peers
Dow Jones  ·  09-18 04:33
Moderna Inc. Stock Climbs 8.5%, Outperforms Peers
Ultragenyx confirms FDA approval of Fayuvi
TIPRANKS  ·  09-18 03:55
Ultragenyx confirms FDA approval of Fayuvi
S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT
Reuters  ·  09-18 03:30
S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT
Moderna Inc Stock (MRNA) Moved Up by 7.25% on Sep 17: Facts Behind the Movement
TradingKey  ·  09-18 01:15
Moderna Inc Stock (MRNA) Moved Up by 7.25% on Sep 17: Facts Behind the Movement
Moderna: Another Day, Another Big Stock Move. is the Cancer Vaccine Rally Back On?
Dow Jones  ·  09-18 00:32
Moderna: Another Day, Another Big Stock Move. is the Cancer Vaccine Rally Back On?
Moderna Shares Hit Four-Week High; Last up 8%
THOMSON REUTERS  ·  09-17 23:09
Moderna Shares Hit Four-Week High; Last up 8%
Nuvation Bio announces FDA approval of sNDA for Ibtrozi
TIPRANKS  ·  09-17 19:35
Nuvation Bio announces FDA approval of sNDA for Ibtrozi
Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes
TIPRANKS  ·  09-17 17:30
Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes
Moderna President Stephen Hoge Disposes of 80,575 Common Shares Worth $11.78 Million
Reuters  ·  09-17 04:49
Moderna President Stephen Hoge Disposes of 80,575 Common Shares Worth $11.78 Million
Cboe data shows mixed options sentiment in Moderna with shares down 2.14%
TIPRANKS  ·  09-16
Cboe data shows mixed options sentiment in Moderna with shares down 2.14%
ASX biotech expands diagnostics portfolio after FDA approval
Morning Star AU  ·  09-16
ASX biotech expands diagnostics portfolio after FDA approval
Barclays downgrades Scholar Rock on valuation after FDA approval
TIPRANKS  ·  09-15
Barclays downgrades Scholar Rock on valuation after FDA approval
Moderna CFO James M. Mock Disposes of 34,836 Common Shares Worth $4.68 Million
Reuters  ·  09-15
Moderna CFO James M. Mock Disposes of 34,836 Common Shares Worth $4.68 Million
Biofrontera announces FDA approval of Ameluz supplemental new drug application
TIPRANKS  ·  09-14
Biofrontera announces FDA approval of Ameluz supplemental new drug application
Scholar Rock Wins FDA Approval for SMA Therapy
TIPRANKS  ·  09-14
Scholar Rock Wins FDA Approval for SMA Therapy

Introduction

Company Name.
YieldMax MRNA Option Income Strategy ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.
Issue price:
--